Please wait while we load the requested 10-K report or click the link below:
Vanda Pharmaceuticals Inc.
|||Vanda recorded 2010 revenue of $35.2 million including royalties and product sales of $8.4 million.|
|||Cash and cash equivalents plus marketable securities at year end 2010 were $198.0 million as compared to $205.3 million at year end 2009.|
|||Monthly prescriptions of Fanapt®, as reported by IMS, increased from over 6,000 in September of 2010 to over 8,000 in December of 2010. For the full year 2010, more than 55,000 prescriptions were written.|
|||Tasimelteon efficacy and safety studies are ongoing in both the U.S. and Europe.|
|||On November 15, 2010, Vanda received a private letter ruling (PLR) from the Internal Revenue Service (IRS) clarifying the companys ability to utilize net operating loss carryforwards for tax purposes.|
Page 1 of 9
The following information was filed by Vanda Pharmaceuticals Inc. (VNDA) on Thursday, February 10, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Vanda Pharmaceuticals Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Vanda Pharmaceuticals Inc..